Celyad Oncology Sa Stock Market Value
| CLYYF Stock | USD 0.15 0.03 16.67% |
| Symbol | Celyad |
Celyad Oncology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Celyad Oncology's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Celyad Oncology.
| 01/01/2025 |
| 12/27/2025 |
If you would invest 0.00 in Celyad Oncology on January 1, 2025 and sell it all today you would earn a total of 0.00 from holding Celyad Oncology SA or generate 0.0% return on investment in Celyad Oncology over 360 days. Celyad Oncology is related to or competes with Molecular Partners, XORTX Therapeutics, Nutriband, ZyVersa Therapeutics, Allarity Therapeutics, Aditxt, and Palisade Bio. Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric ant... More
Celyad Oncology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Celyad Oncology's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Celyad Oncology SA upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.19) | |||
| Maximum Drawdown | 51.22 |
Celyad Oncology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Celyad Oncology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Celyad Oncology's standard deviation. In reality, there are many statistical measures that can use Celyad Oncology historical prices to predict the future Celyad Oncology's volatility.| Risk Adjusted Performance | (0.12) | |||
| Jensen Alpha | (1.33) | |||
| Total Risk Alpha | (1.93) | |||
| Treynor Ratio | (0.77) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Celyad Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Celyad Oncology SA Backtested Returns
Celyad Oncology SA secures Sharpe Ratio (or Efficiency) of -0.18, which signifies that the company had a -0.18 % return per unit of risk over the last 3 months. Celyad Oncology SA exposes nineteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Celyad Oncology's Risk Adjusted Performance of (0.12), standard deviation of 6.74, and Mean Deviation of 2.29 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.58, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Celyad Oncology will likely underperform. At this point, Celyad Oncology SA has a negative expected return of -1.2%. Please make sure to confirm Celyad Oncology's standard deviation, skewness, as well as the relationship between the Skewness and day typical price , to decide if Celyad Oncology SA performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.57 |
Modest predictability
Celyad Oncology SA has modest predictability. Overlapping area represents the amount of predictability between Celyad Oncology time series from 1st of January 2025 to 30th of June 2025 and 30th of June 2025 to 27th of December 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Celyad Oncology SA price movement. The serial correlation of 0.57 indicates that roughly 57.0% of current Celyad Oncology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.57 | |
| Spearman Rank Test | 0.62 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Celyad Oncology SA lagged returns against current returns
Autocorrelation, which is Celyad Oncology pink sheet's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Celyad Oncology's pink sheet expected returns. We can calculate the autocorrelation of Celyad Oncology returns to help us make a trade decision. For example, suppose you find that Celyad Oncology has exhibited high autocorrelation historically, and you observe that the pink sheet is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Celyad Oncology regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Celyad Oncology pink sheet is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Celyad Oncology pink sheet is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Celyad Oncology pink sheet over time.
Current vs Lagged Prices |
| Timeline |
Celyad Oncology Lagged Returns
When evaluating Celyad Oncology's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Celyad Oncology pink sheet have on its future price. Celyad Oncology autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Celyad Oncology autocorrelation shows the relationship between Celyad Oncology pink sheet current value and its past values and can show if there is a momentum factor associated with investing in Celyad Oncology SA.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Celyad Pink Sheet
Celyad Oncology financial ratios help investors to determine whether Celyad Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Celyad with respect to the benefits of owning Celyad Oncology security.